Oncologists use measurement of response as an indicator that the therapy they are administering is effective. This information can then be used to decide whether to continue, change, or stop therapy ...
Phase II study of NGR-hTNF, a vascular targeting agent, in combination with doxorubicin in patients with relapsed small cell lung cancer (SCLC). Background: Carcinoembryonic antigen (CEA, CEACAM5) is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results